Necrotizing myopathies: Beyond statins

Andrew L. Mammen

Research output: Contribution to journalArticle

Abstract

Purpose of review: This review discusses the spectrum of diseases associated with a necrotizing muscle biopsy. Although patients with toxic myopathies, endocrine dysfunction, and heritable myopathies may have prominent necrosis on muscle biopsy, immune-mediated myopathies are emphasized here. Recent findings: A decade ago, immune-mediated necrotizing myopathy was recognized as a distinct form of myositis. Recent evidence now suggests that immune-mediated necrotizing myopathy is not one disease, but can be divided on the basis of the presence of distinct autoantibodies recognizing either the signal recognition particle or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Anti-HMG-CoA reductase-positive patients can be further subdivided into those with and without statin exposure, the latter of which may be particularly refractory to immunosuppressive therapy. Summary: A significant number of patients with autoimmune myopathy have a predominantly necrotizing muscle biopsy with minimal lymphocytic infiltration. This biopsy finding occurs in various forms myositis, including the antisynthetase syndrome, scleroderma-associated myopathy, antisignal recognition particle-associated myopathy, statin-associated anti-HMG-CoA reductase-positive autoimmune myopathy, and statin-naïve anti-HMG-CoA reductase-positive myopathy. Future progress in elucidating pathogenic mechanisms and defining optimal treatment strategies may depend upon recognizing these distinct forms of myositis and analyzing them as separate entities.

Original languageEnglish (US)
Pages (from-to)679-683
Number of pages5
JournalCurrent Opinion in Rheumatology
Volume26
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscular Diseases
Myositis
Oxidoreductases
Biopsy
Muscles
Signal Recognition Particle
Poisons
Immunosuppressive Agents
Autoantibodies
Necrosis

Keywords

  • Anti-HMG-CoA reductase
  • Autoimmune
  • Muscle
  • Myopathy
  • Myositis
  • Necrotizing
  • Signal recognition particle
  • Statin

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Necrotizing myopathies : Beyond statins. / Mammen, Andrew L.

In: Current Opinion in Rheumatology, Vol. 26, No. 6, 2014, p. 679-683.

Research output: Contribution to journalArticle

Mammen, Andrew L. / Necrotizing myopathies : Beyond statins. In: Current Opinion in Rheumatology. 2014 ; Vol. 26, No. 6. pp. 679-683.
@article{60cb3a67b7d3408d941076476b83ec5c,
title = "Necrotizing myopathies: Beyond statins",
abstract = "Purpose of review: This review discusses the spectrum of diseases associated with a necrotizing muscle biopsy. Although patients with toxic myopathies, endocrine dysfunction, and heritable myopathies may have prominent necrosis on muscle biopsy, immune-mediated myopathies are emphasized here. Recent findings: A decade ago, immune-mediated necrotizing myopathy was recognized as a distinct form of myositis. Recent evidence now suggests that immune-mediated necrotizing myopathy is not one disease, but can be divided on the basis of the presence of distinct autoantibodies recognizing either the signal recognition particle or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Anti-HMG-CoA reductase-positive patients can be further subdivided into those with and without statin exposure, the latter of which may be particularly refractory to immunosuppressive therapy. Summary: A significant number of patients with autoimmune myopathy have a predominantly necrotizing muscle biopsy with minimal lymphocytic infiltration. This biopsy finding occurs in various forms myositis, including the antisynthetase syndrome, scleroderma-associated myopathy, antisignal recognition particle-associated myopathy, statin-associated anti-HMG-CoA reductase-positive autoimmune myopathy, and statin-na{\"i}ve anti-HMG-CoA reductase-positive myopathy. Future progress in elucidating pathogenic mechanisms and defining optimal treatment strategies may depend upon recognizing these distinct forms of myositis and analyzing them as separate entities.",
keywords = "Anti-HMG-CoA reductase, Autoimmune, Muscle, Myopathy, Myositis, Necrotizing, Signal recognition particle, Statin",
author = "Mammen, {Andrew L.}",
year = "2014",
doi = "10.1097/BOR.0000000000000106",
language = "English (US)",
volume = "26",
pages = "679--683",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Necrotizing myopathies

T2 - Beyond statins

AU - Mammen, Andrew L.

PY - 2014

Y1 - 2014

N2 - Purpose of review: This review discusses the spectrum of diseases associated with a necrotizing muscle biopsy. Although patients with toxic myopathies, endocrine dysfunction, and heritable myopathies may have prominent necrosis on muscle biopsy, immune-mediated myopathies are emphasized here. Recent findings: A decade ago, immune-mediated necrotizing myopathy was recognized as a distinct form of myositis. Recent evidence now suggests that immune-mediated necrotizing myopathy is not one disease, but can be divided on the basis of the presence of distinct autoantibodies recognizing either the signal recognition particle or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Anti-HMG-CoA reductase-positive patients can be further subdivided into those with and without statin exposure, the latter of which may be particularly refractory to immunosuppressive therapy. Summary: A significant number of patients with autoimmune myopathy have a predominantly necrotizing muscle biopsy with minimal lymphocytic infiltration. This biopsy finding occurs in various forms myositis, including the antisynthetase syndrome, scleroderma-associated myopathy, antisignal recognition particle-associated myopathy, statin-associated anti-HMG-CoA reductase-positive autoimmune myopathy, and statin-naïve anti-HMG-CoA reductase-positive myopathy. Future progress in elucidating pathogenic mechanisms and defining optimal treatment strategies may depend upon recognizing these distinct forms of myositis and analyzing them as separate entities.

AB - Purpose of review: This review discusses the spectrum of diseases associated with a necrotizing muscle biopsy. Although patients with toxic myopathies, endocrine dysfunction, and heritable myopathies may have prominent necrosis on muscle biopsy, immune-mediated myopathies are emphasized here. Recent findings: A decade ago, immune-mediated necrotizing myopathy was recognized as a distinct form of myositis. Recent evidence now suggests that immune-mediated necrotizing myopathy is not one disease, but can be divided on the basis of the presence of distinct autoantibodies recognizing either the signal recognition particle or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Anti-HMG-CoA reductase-positive patients can be further subdivided into those with and without statin exposure, the latter of which may be particularly refractory to immunosuppressive therapy. Summary: A significant number of patients with autoimmune myopathy have a predominantly necrotizing muscle biopsy with minimal lymphocytic infiltration. This biopsy finding occurs in various forms myositis, including the antisynthetase syndrome, scleroderma-associated myopathy, antisignal recognition particle-associated myopathy, statin-associated anti-HMG-CoA reductase-positive autoimmune myopathy, and statin-naïve anti-HMG-CoA reductase-positive myopathy. Future progress in elucidating pathogenic mechanisms and defining optimal treatment strategies may depend upon recognizing these distinct forms of myositis and analyzing them as separate entities.

KW - Anti-HMG-CoA reductase

KW - Autoimmune

KW - Muscle

KW - Myopathy

KW - Myositis

KW - Necrotizing

KW - Signal recognition particle

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84927759355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927759355&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000106

DO - 10.1097/BOR.0000000000000106

M3 - Article

C2 - 25203117

AN - SCOPUS:84927759355

VL - 26

SP - 679

EP - 683

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 6

ER -